GPC3 and hepatocellular carcinoma: Recently, a double-blind, phase II trial of GC33 in 185 patients with chemotherapy-unresponsive HCC showed that, although Codrituzumab therapy itself was ineffective, when increasing Codrituzumab exposure, the levels of GPC3 and CD16 in circulating immune cells could predict the efficacy of the drug, suggesting that precision Codrituzumab therapy with this perspective may have potential for treating HCC (64).